Table 1 Average patient and disease characteristics for all included visits with Disease Activity Score ≤ 2.4 but > 1.6
No treatment intensification | Treatment intensification | |
|---|---|---|
Age, years, mean (SD) | 52.6 (12.6) | 51.0 (12.4) |
Sex, n (% female) | 46 (78.9) | 39 (68.4) |
Treatment arm | ||
Early remission | 46.2 | 57.2 |
MTX + SSZ + HCQ + prednisone | 20.9 | 19.9 |
MTX + adalimumab | 19.1 | 16.0 |
Out of protocol | 13.8 | 6.7 |
Symptom duration, weeks, median (IQR) | 20 (9–35) | 19 (9–32) |
Diagnosed RA, % meeting 2010 ACR/EULAR criteria | 46 (79.2) | 47 (84.5) |
Anti-citrullinated protein antibodies, % positive | 34 (57.6) | 35 (61.9) |
Rheumatoid factor, % positive | 33 (58.9) | 34 (63.0) |
Health Assessment Questionnaire (0–3)a, mean (SD) | 0.78 (0.56) | 0.63 (0.48) |
Disease Activity Score, mean (SD) | 1.95 (0.23) | 1.99 (0.23) |
Tender joint count, median (IQR) | 2 (2–4) | 3 (2–4) |
Swollen joint count, median (IQR) | 0 (0–1) | 1 (0–2) |
VAS general health (0–100)b, mean (SD) | 31.0 (19.6) | 31.7 (20.3) |
Erythrocyte sedimentation rate, mm/h, median (IQR) | 15.7 (13.0) | 13.9 (11.2) |